Abstract: Biological agents have provided new therapeutic options for nail psoriasis. Among them, anti-TNF-α inhibitors, anti-IL-17 inhibitors, and anti-IL-12/23 inhibitors have all demonstrated favorable long-term efficacy. As a novel domestic anti-IL-17A monoclonal antibody, fonakizumab is mainly indicated for moderate-to-severe plaque psoriasis, with limited clinical reports on its use in nail psoriasis. Herein, we report a case of multi-nail involved nail psoriasis. After exclusion of contraindications, the patient was treated with fonakizumab. Clinical efficacy was observed at 2 months, and complete nail recovery was achieved at the 6-month follow-up.

Key words: nail psoriasis, vunakizumab, IL-17A inhibitor